MarketPulse

clinical trial pause

2 articles
GlobeNewswire Inc.GlobeNewswire Inc.··Hagens Berman

Aardvark Therapeutics Stock Crashes 56% as Lead Drug Halted Over Cardiac Safety

Aardvark Therapeutics ($AARD) plummeted 56% after pausing Phase 3 HERO trial for ARD-101 due to cardiac safety concerns, contradicting prior safety assurances.
AARDstock declinesecurities investigation
GlobeNewswire Inc.GlobeNewswire Inc.··Pomerantz Llp

Aardvark Therapeutics Stock Plummets 56% as Law Firm Probes Cardiac Safety Concerns

Pomerantz Law Firm investigates Aardvark Therapeutics after Phase 3 trial pause over cardiac safety issues. Stock crashed 56.2% to $5.47.
AARDsecurities fraudclass action lawsuit